Management of epilepsy in oncological patients

Neurologist

Volumn 14, Issue 6 SUPPL. 1, 2008, Pages

  Villanueva, Vicente ^a   Codina, Montserrat ^b   Elices, Eloy ^c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Clinica Rotger   (Spain)

Author keywords

Anticonvulsants therapeutic use; Antineoplastics; Cancer drug therapy; Epilepsy drug therapy; Oncology drug therapy

Indexed keywords

ANALGESIC AGENT; BUSULFAN; CARBAMAZEPINE; CARBAPENEM; CEPHALOSPORIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETHOSUXIMIDE; ETIRACETAM; ETOPOSIDE; GABAPENTIN; IRINOTECAN; METHOTREXATE; NITROSOUREA; OXCARBAZEPINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; QUINOLONE; THIOTEPA; TIAGABINE; TOPIRAMATE; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; ZONISAMIDE;

ASTROCYTOMA; BRAIN INFECTION; BRAIN LYMPHOMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOMATOUS MENINGITIS; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; EPILEPSY; GLIOBLASTOMA; GLIOMA; HUMAN; INFECTIOUS COMPLICATION; MENINGIOMA; METABOLIC DISORDER; NEUROEPITHELIOMA; OLIGODENDROGLIOMA; PARANEOPLASTIC NEUROPATHY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; SEIZURE; STEVENS JOHNSON SYNDROME; TERATOMA; TREATMENT WITHDRAWAL;

ANTICONVULSANTS; BRAIN NEOPLASMS; EPILEPSY; HUMANS;

EID: 57649123276     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000340791.53413.f4     Document Type: Review

References (102)

1. Herman ST. Epilepsy after brain insult: targeting epileptogenesis. Neurology. 2002;59(Suppl):S21-S26.
2. Olafsson E, Ludvigsson P, Gudmundsson G, et al. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol. 2005;4:627-634.
3. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34:453-468.
4. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421-430.
5. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1886-1893.
6. Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res. 2000;38:45-52.
7. Arita K, Ikawa F, Kurisu K, et al. The relationship between magnetic resonance imaging findings and clinical manifestations of hypothalamic hamartoma. J Neurosurg. 1999;91:212-220.
8. Sirven JI, Wingerchuk DM, Drazkowski JF, et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79:1489-1494.
9. Wolf HK, Roos D, Blumcke I, et al. Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol. 1996;91:376-384.
10. Riva M. Brain tumoral epilepsy: a review. Neurol Sci. 2005;26(Suppl. 1):S40-S42.
11. Beaumont A, Whittle IR. The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien). 2000;142:1-15.
12. Schaller B. Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis. Acta Neurol Scand. 2005;111:75-83.
13. Brodtkorb E, Nakken KO, Steinlein OK. No evidence for a seriously increased malignancy risk in LGI1-caused epilepsy. Epilepsy Res. 2003;56:205-208.
14. Larson DA, Rubenstein JL, McDermott MW. Treatment of metastatic cancer. In: De Vita VT, et al., eds. Cancer: principles and practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
15. Villemure JG, de Tribolet N. Epilepsy in patients with central nervous system tumors. Curr Opin Neurol. 1996;9:424-428.
16. Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol. 2002;249:1357-1369.
17. Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry. 2007;78:342-349.
18. Baiges-Octavio JJ, Huerta-Villanueva M. Meningeal carcinomatosis [in Spanish]. Rev Neurol. 2000;31:1237-1241
19. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol. 1996;53:626-632.
20. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev. 1999;25:103-119.
21. Beristain X, Azzarelli B. The neurological masquerade of intravascular lymphomatosis. Arch Neurol. 2002;59:439-443.
22. Baumann TP, Hurwitz N, Karamitopolou-Diamantis E, et al. Diagnosis and treatment of intravascular lymphomatosis. Arch Neurol. 2000;57:374-377.
23. Taillibert S, Chodkiewicz C, Laigle-Donadey F, et al. Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. J Neurooncol. 2006;76:201-205.
24. Jennings MT, Frenchman M, Shehab T, et al. Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol. 1995;10:37-45.
25. Maton B, Resnick T, Jayakar P, et al. Epilepsy surgery in children with giomatosis cerebri. Epilepsia. 2007;48:1485-1490.
26. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135-1140.
27. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123:1481-1494.
28. Lawn ND, Westmoreland BF, Kiely MJ, et al. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc. 2003;78:1363-1368.
29. Schott JM. Limbic encephalitis: a clinicians guide. Pract Neurol. 2006;6:143-153.
30. Bien CG, Elger CE. Limbic encephalitis: a cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav. 2007;10:529-538.
31. Espay AJ, Kumar V, Sarpel G. Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus. J Neurol Sci. 2006;246:149-152.
32. Dalmau J, Bataller L. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am. 2006;20:1319-1335.
33. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology. 1985;35:538-543.
34. Voltz R, Gultekin SH, Rosenfeld MR, et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999;340:1788-1795.
35. Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 1996;61:270-278.
36. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001;50:301-311.
37. Graus F, Vincent A, Pozo-Rosich P, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol. 2005;165:166-171.
38. Sabater L, Gomez-Choco M, Saiz A, Graus F. BR serine/threonine kinase 2: a new autoantigen in paraneoplastic limbic encephalitis. J Neuroimmunol. 2005;170:186-190.
39. Petit T, Janser JC, Achour NR, et al. Paraneoplastic temporal lobe epilepsy and anti-Yo autoantibody. Ann Oncol. 1997;8:919.
40. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127:2331-2338.
41. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004;63:282-286.
42. Bien CG, Urbach H, Schramm J, et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology. 2007;69:1236-1244.
43. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13:682-690.
44. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127:1831-1844.
45. Mut M, Schiff D, Dalmau J. Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua. J Neurooncol. 2005;72:63-66.
46. Shavit YB, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol. 1999;45:255-258.
47. Kinirons P, O'Dwyer JP, Connolly S, Hutchinson M. Paraneoplastic limbic encephalitis presenting as lingual epilepsia partialis continua. J Neurol. 2006;253:256-257.
48. Tonomura Y, Kataoka H, Hara Y, et al. Clinical analysis of paraneoplastic encephalitis associated with ovarian teratoma. J Neurooncol. 2007;84:287-292.
49. Jung KY, Youn J, Chung CS. Opsoclonus-myoclonus syndrome in an adult with malignant melanoma. J Neurol. 2006;253:942-943.
50. Bromfield EB. Epilepsy in patients with brain tumors and other cancers. Rev Neurol Dis. 2004;1(Suppl. 1):S27-S33.
51. Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann Neurol. 1992;31:268-273.
52. Sander JW, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta Neurol Scand Suppl. 2003;180:16-22.
53. Gregory RE, Grossman S, Sheidler VR. Grand mal seizures associated with high-dose intravenous morphine infusions: incidence and possible etiology. Pain. 1992;51:255-258.
54. Cestari DM, Weine DM, Panageas KS, et al. Stroke in patients with cancer: incidence and etiology. Neurology. 2004;62:2025-2030.
55. Lebrun C, Thomas P, Peyrade F, Frenay M. Epilepsy and cancer [in French]. Rev Med Interne. 1998;19:325-333
56. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50:6203-6207.
57. Steeghs N, de Jongh FE, Sillevis Smitt PA, van den Bent MJ. Cisplatin-induced encephalopathy and seizures. Anticancer Drugs. 2003;14:443-446.
58. Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr. 1978;93:516-518.
59. Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother. 2000;34:35-38.
60. Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol. 1986;4:1253-1261.
61. Nieto Y, Cagnoni PJ, Bearman SI, et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res. 1999;5:501-506.
62. Goyal M, Bangert BA, Wiznitzer M. Mesial temporal sclerosis in acute childhood leukemias. Epilepsia. 2003;44:131-134.
63. Dropcho EJ. Neurotoxicity of cancer chemotherapy. Semin Neurol. 2004;24:419-426.
64. New PZ. Neurological complications of chemotherapeutic and biological agents. In: Continuum, lifelong learning in neurology. American Academy of Neurology: Lippincott Williams & Wilkins; 2005. pp. 116-160.
65. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol. 1991;9:694-704.
66. Legroux-Crespel E, Lafaye S, Mahe E, et al. Seizures during interferon alpha therapy: three cases in dermatology [in French]. Ann Dermatol Venereol. 2003;130:202-204
67. Faraci M, Lanino E, Dallorso S, et al. Mesial temporal sclerosis - a late complication in four allogeneic pediatric recipients with persistent seizures after an acute episode of cyclosporine-A neurotoxicity. Bone Marrow Transplant. 2003;31:919-922.
68. McKenzie MR, Souhami L, Caron JL, et al. Early and late complications following dynamic stereotactic radiosurgery and fractionated stereotactic radiotherapy. Can J Neurol Sci. 1993;20:279-285.
69. Dea S. Complications of stereostatic radiosurgery in patients with brain metastases. Considerations for deep and functional brain tumor locations. Neurosurg Q. 2007;17:81-91.
70. Burn S, Gunny R, Phipps K, et al. Incidence of cavernoma development in children after radiotherapy for brain tumors. J Neurosurg. 2007;106:379-383.
71. Wick W, Menn O, Meisner C, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie. 2005;28:391-396.
72. Wagner GL, Wilms EB, Van Donselaar CA, Vecht Ch J. Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure. 2003;12:585-586.
73. Perry JR, Sawka C. Add-on gabapentin for refractory seizures in patients with brain tumours. Can J Neurol Sci. 1996;23:128-131.
74. Striano S, Striano P, Boccella P, et al. Tiagabine in glial tumors. Epilepsy Res. 2002;49:81-85.
75. Oberndorfer S, Piribauer M, Marosi C, et al. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72:255-260.
76. Relling MV, Pui CH, Sandlund JT, et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet. 2000;356:285-290.
77. Bourg V, Lebrun C, Chichmanian RM, et al. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol. 2001;12:217-219.
78. Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain. 2005;128:7-17.
79. Armijo JA, Adin J, Herranz JL. Interacciones de los antiepilé pticos entre si y con otros fármacos. Barcelona:Exter; 2005. pp. 56-60.
80. Pohlmann-Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand. 2003;108:142-145.
81. Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2003;2:404-409.
82. Delattre JY, Safai B, Posner JB. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology. 1988;38:194-198.
83. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361-1368.
84. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259-266.
85. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol. 1999;17:2762-2771.
86. Pace A, Vidiri A, Galie E. et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14:1722-1726.
87. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715-1721.
88. Ngo L, Nei M, Glass J. Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia. 2006;47:1237-1238.
89. Frenay MP, Fontaine D, Vandenbos F, Lebrun C. First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur J Neurol. 2005;12:685-690.
90. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46:203-207.
91. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013-2021.
92. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. NeuroOncol. 2006;8:189-193.
93. de la Fuente BP, Dalmau J, Rosenfeld M. Glioma therapy up-date [in Spanish]. Neurologia. 2007;22:159-169
94. van Breemen MS, Vecht CJ. Optimal seizure management in brain tumor patients. Curr Neurol Neurosci Rep. 2005;5:207-213.
95. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108:227-235.
96. Luyken C, Blumcke I, Fimmers R, et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia. 2003;44:822-830.
97. Morris HH, Estes ML, Gilmore R, et al. Chronic intractable epilepsy as the only symptom of primary brain tumor. Epilepsia. 1993;34:1038-1043.
98. Zentner J, Hufnagel A, Wolf HK, et al. Surgical treatment of neoplasms associated with medically intractable epilepsy. Neurosurgery. 1997;41:378-386. discussion 386-377.
99. Britton JW, Cascino GD, Sharbrough FW, Kelly PJ. Low-grade glial neoplasms and intractable partial epilepsy: efficacy of surgical treatment. Epilepsia. 1994;35:1130-1135.
100. Pilcher WH, Silbergeld DL, Berger MS, Ojemann GA. Intraoperative electrocorticography during tumor resection: impact on seizure outcome in patients with gangliogliomas. J Neurosurg. 1993;78:891-902.
101. Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology. 1993;43:1599-1601.
102. Chalifoux R, Elisevich K. Effect of ionizing radiation on partial seizures attributable to malignant cerebral tumors. Stereotact Funct Neurosurg. 1997;67:169-182.